Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues

European Review for Medical and Pharmacological Sciences

Volumn 14, Issue 4, 2010, Pages 347-351

  Bodei, L ^a   Pepe, G ^a   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

177Lu DOTATATE; 90Y DOTATOC; PRRT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; ANTINEOPLASTIC AGENT; DOTATATE LU 177; DOTATOC Y 90; OCTREOTATE; OCTREOTIDE[3 TYROSINE]; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

BLOOD TOXICITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; RADIATION DOSE; RADIATION RESPONSE; RADIATION SAFETY; RECEPTOR AFFINITY; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; LUTETIUM; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; SOMATOSTATIN; YTTRIUM RADIOISOTOPES;

EID: 77953169930     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. MODLIN IM, OBERG K, CHUNG DC, JENSEN RT, DE HERDER WW, THAKKER RV, CAPLIN M, DELLE FAVE G, KALTSAS GA, KRENNING EP, MOSS SF, NILSSON O, RINDI G, SALAZAR R, RUSZNIEWSKI P, SUNDIN A. Gastroenteropancreatic neuroendocrine tumors. Lancet Oncol 2008; 9: 61-72.
2. LAMBERTS SW, BAKKER WH, REUBI JC, KRENNING EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323: 1246-1249. (Pubitemid 20366530)
3. REUBI JC, SCHAER JC, LAISSUE JA, WASER B. Somatostatin receptors and theirs subtypes in human tumors and in peritumoral vessels. Metabolism 1996; 45(8 Suppl 1): 39-41. (Pubitemid 26281937)
4. 111In-DTPAO]octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32: 110-122.
5. 90Y-DOTATOC. Eur J Nucl Med 1999; 26: 877-886.
6. BRANS B, BODEI L, GIAMMARILE F, LINDEN O, LUSTER M, OYEN W, TENNVALL J. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur J Nucl Med Mol Imaging 2007; 34: 772-786.
7. BERNARD BF, KRENNING EP, BREEMANWA, ROLLEMAN EJ, BAKKER WH, VISSER TJ, MĀCKE H, DE JONG M. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997; 38: 1929-1933.
8. DE JONG M, KRENNING EP. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002; 43: 617-620. (Pubitemid 34507111)
9. PERICO ME, CHINOL M, NACCA A, LUISON E, PAGANELLI G, CANEVARI S. The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier molecole. J Nucl Med 2001; 42: 1697-1703.
10. BODEI L, CREMONESI M, ZOBOLI S, GRANA C, BARTOLOMEI M, ROCCA P, CARACCIOLO M, MĀCKE HR, CHINOL M, PAGANELLI G. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003; 30: 207-216.
11. 177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-2762.
12. DE JONG M, VALKEMA R, JAMAR F, KVOLS LK, KWEKKEBOOM DJ, BREEMAN WA, BAKKER WH, SMITH C, PAUWELS S, KRENNING EP. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32: 133-140.
13. KWEKKEBOOM DJ, MUELLER-BRAND J, PAGANELLI G, ANTHONY LB, PAUWELS S, KVOLS LK, O'DORISIO T, VALKEMA R, BODEI L, CHINOL M, MAECKE HR, KRENNING EP. An overview of the results of peptide receptor radionuclide therapy with 3 different radiolabeled somatostatin analogues. J Nucl Med 2005; 46: 62S 66S.
14. WALDHERR C, PLESS M, MAECKE HR, SCHUMACHER T, CRAZZOLARA A, NITZSCHE EU, HALDEMANN A, MUELLER-BRAND J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002; 43: 610-616.
15. 90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006; 36: 147-156.
16. BODEI L, CREMONESI M, GRANA C, ROCCA P, BARTOLOMEI M, CHINOL M, PAGANELLI G. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31: 1038-1046.
17. HEPPELER A, FROIDEVAUX S, MĀCKE HR. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur 1999; 7: 1974-1981.
18. DE JONG M, KWEKKEBOOM D, VALKEMA R, KRENNING EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med 2003; 30: 463-469.
19. 177Lu-DOTA0,Tyr3] octreotate. J Clin Oncol 2004; 22: 2724-2729. (Pubitemid 41103761)
20. 177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
21. VALKEMA R, PAUWELS SA, KVOLS LK, KWEKKEBOOM DJ, JAMAR F, DE JONG M, BARONE R, WALRAND S, KOOIJ PP, BAKKER WH, LASHER J, KRENNING EP. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J Nucl Med 2005; 46: 83S-91S.
22. CREMONESI M, FERRARI M, BODEI L, TOSI G, PAGANELLI G. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med 2006; 47: 1467-1475.
23. 177)Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008; 35: 1847-1856.
24. 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28: 426-434.
25. 177Lu- DOTATATE in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2006; 33(Suppl 2): S214.
26. 177Lu-DOTA0, Tyr3]-octreotate) in ectopic Cushing syndrome from a metastatic gastrinoma: a promising proposal. Endocr Pract 2008; 14: 213-218.
27. 177)Lu- octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 743-748.
28. REUBI JC, MĀCKE HR, KRENNING EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46(Suppl. 1): 67-75.